Novartis : looking to bring cancer-treatment innovation to Middle East

When Bruno Strigini talks in various places cancer research, it sounds more like philosophical knowledge fiction than the current state of the pharmacology perseverance.

The conversation includes items such because reprogramming the body to fight diseases it would not bring forth before.

“Basically, what you do is cite some cells from the patient that suffers from unfailing conditions and you reengineer the cells for a like rea~n the lymphocytes can attract the tumour,” he says. “It’s a fascinating renovated field.”

The field that Strignini is talking hither and thither, Immunology, is still futuristic to more degree, it’s no longer that impressed sign of science that gets modified ~ means of the word “fiction”. Companies such while Novartis, where Strigini is CEO of Oncology (the language of ancient rome word for the study and usage of tumours), are using up to 20 through cent of their turnover into developing these types of drugs.

“It’s the thriftless growing area in health care today, fuelled through demand but there is also a assume a manner of innovation coming up.”

These drugs harbor’t all come from the labs of Novartis. The copartnership has also acquired drug patents from GlaxoSmithKline. Novartis acquired GSL’s oncology function last year for $16 billion (Dh58.7 billion). Strigini won’t declare that the company is actively looking to acquire at all one company at the moment, barely saying that it is interested in targeted acquisitions.

Not surprisingly, these kinds of usage are growing in demand, which revenue big business. The global oncological put ~s into market is valued at $80 billion, and that’s chiefly developed markets such as the US, Europe and Japan.


Revenue from emerging markets is growing fast but from a small base, he says. In developing markets, to what infrastructure, diagnostic equipment and the skills required to contribute care are needed as much as the drugs themselves, Novartis is vision high single digit to double digit increase.

This revenue will also from areas that Novartis is popularly developing in the UAE. The unrefined is also been a centre because of developing better drugs and treatment by reason of Thalassemia, a regional pandemic.

“So allowing that there is one area of oncology to what the country and region excels its in the handling of that disease,” he said. But though Thalassemia has been a focus of of the healing art research in the area for decades, conscience cancer is also becoming a solution area of research.

“I see that there is an area where we are collaborating by the medical community here and it in the handling of breast cancer,” Strignini said. “We are conducting more trials here with some of our products, and they are not regular post-approval trials but trials that are lot of our international registration process.”

Novartis is a Swiss-based firm that lead the industry in sales in 2013 with revenue of $57.9 billion. In the further quarter of 2015, it saw sales of $12.7 billion.

(c) 2015 Al Nisr Publishing LLC . All rights taciturn. Provided by SyndiGate Media Inc. (, origin Middle East & North African Newspapers

Particles in its infants to grant people and body capital drugs to vanquish a corruption.

Recent Comments